Iovance Biotherapeutics share price logo

Iovance Biotherapeutics

NASDAQ: IOVA

Mid Cap

$11.00

+0.20

(+1.85%)

as on

Iovance Biotherapeutics Stock Performance

as on September 26, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $10.69
    $11.13
    downward going graph

    2.82%

    Downside

    1.18%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $1.76
    $11.13
    downward going graph

    84.00%

    Downside

    1.18%

    Upside

    downward going graph

Iovance Biotherapeutics share price movements today

Previous Close
$10.80
Open
$10.91
Volume
12.2M
Market Cap
$4.9B
Day's Low - High
$10.69 - $11.13
52 Week Low - High
$1.76 - $11.13

Iovance Biotherapeutics Historical Returns

1 Month Return
+ 36.14 %
3 Month Return
+ 158.82 %
1 Year Return
+ 421.33 %
3 Year Return
+ 147.75 %
5 Year Return
-55.93 %

Iovance Biotherapeutics Stock Fundamentals & Key Indicators

Check Iovance Biotherapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$4.9B

EPS (TTM)

-0.7

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-15.43

Industry PE ratio

-12.76

PEG Ratio

-0.25636074988721713

EBITDA

-262.8M

Revenue (TTM)

325.0M

Profit Margin

116.30%

Return On Equity TTM

-40.51%

Iovance Biotherapeutics Stock Valuation

Track how Iovance Biotherapeutics P/E has moved over time to understand its valuation trends.

Iovance Biotherapeutics in the last 5 years

  • Overview

  • Trends

Lowest (-8.56x)

December 31, 2021

Industry (-12.76x)

December 31, 2025

Today (-2.50x)

December 31, 2025

Highest (-2.50x)

December 31, 2025

LowHigh

Today’s Price to Earnings Ratio: -2.50x

Iovance Biotherapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Iovance Biotherapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
StrongBuy$4.9B-55.93%-15.43116.30%0.00%
Neutral$77.8B-53.76%-24.41-12.57%0.00%
StrongBuy$132.4B186.58%30.1686.04%0.00%
Buy$82.8B23.34%19.0184.86%0.46%

Stock Returns calculator for Iovance Biotherapeutics Stock including INR - Dollar returns

The Iovance Biotherapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Iovance Biotherapeutics investment value today

Current value as on today

₹5,63,149

Returns

₹4,63,149

(+463.15%)

Returns from Iovance Biotherapeutics Stock

₹4,21,327 (+421.33%)

Dollar Impact

₹41,822 (+41.82%)

Analyst Recommendation on Iovance Biotherapeutics Stock

Based on 4 analysts

BUY

75.00%

Buy

25.00%

Hold

0.00%

Sell

Based on 4 analysts, 75% of analysts recommend a 'BUY' rating for Iovance Biotherapeutics. Average target price of $10.7

Iovance Biotherapeutics Share Price Target

Get share price movements and forecasts by analysts on Iovance Biotherapeutics.

What analysts predicted

-2.8%DOWNSIDE

Target Price

$10.7

Current Price

$11

Analyzed by

4 Analysts

High

$15

Target

$10.70

Low

$7

Iovance Biotherapeutics target price $10.7, a slight downside of -2.8% compared to current price of $11. According to 4 analysts rating.

Indian Investors' Interest in Iovance Biotherapeutics Stock

Investment in Iovance Biotherapeutics Shares on INDmoney has dropped by -2.70% in the last 30 days, indicating reduced investment activity.

Time period: to

Change:-2.70% versus previous 30 day period

Search interest for Iovance Biotherapeutics Stock has decreased by -17% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-17% versus previous 30 day period

Iovance Biotherapeutics Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
0
31
58
73
49
59
67
86
71
99
Gross Profit
-6
0
18
28
0
3
66
187
70
54
Operating Income
-117
-101
-89
-86
-121
-113
-94
-73
-81
-51
EBITDA
-104
-87
-77
-65
-106
-97
-84
-67
-71
-39
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
9
10
11
11
11
11
9
3
8
9
Income Before Tax
-114
-98
-85
-77
-118
-109
-93
-71
-79
-48
Income Tax Expense
-1
-1
-1
1
-1
1
-2
0
0
-1
Net Income
-112
-97
-83
-78
-116
-111
-91
-71
-79
-47
Net Profit Margin
-915.52%
-0.84%
31.99%
38.20%
-0.85%
5.48%
97.91%
215.85%
98.57%
54.56%

Iovance Biotherapeutics Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
-
-
-
-
1
164
263
Gross Profit
0
0
-8
-
-
-
-9
40
256
Operating Income
-92
-128
-206
-261
-342
-398
-460
-395
-403
EBITDA
-91
-122
-189
-260
-328
-371
-414
-331
-357
Interest Expense
-
-
-
-
-
2
-
-
-
Depreciation
0
0
8
1
13
21
33
43
35
Income Before Tax
-92
-123
-197
-259
-342
-395
-447
-375
-393
Income Tax Expense
-
-
-
-
-
-
-3
-2
-2
Net Income
-92
-123
-197
-259
-342
-395
-444
-372
-390
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
-804.54%
24.43%
97.23%

Iovance Biotherapeutics Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-112
-97
-83
-78
-116
-111
-91
-71
-79
-47
Operating Cash Flow
-122
-98
-58
-73
-103
-67
-78
-52
-72
-60
Investing Cash Flow
-111
40
-48
23
15
13
17
0
11
-74
Financing Cash Flow
193
152
41
2
143
13
88
56
94
49
Change in Cash
-40
94
-64
-48
55
-39
25
4
-157
-190

Iovance Biotherapeutics Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-92
-123
-197
-259
-342
-395
-444
-372
-390
Operating Cash Flow
-78
-101
-158
-205
-227
-292
-361
-352
-302
Investing Cash Flow
58
-386
90
-317
0
256
-155
-96
47
Financing Cash Flow
58
424
6
576
239
190
462
390
300
Change in Cash
38
-63
-62
53
11
153
-56
-59
47

Mutual Funds that own Iovance Biotherapeutics Stock

Check out the Mutual Funds with significant holdings in Iovance Biotherapeutics.

Funds
Holdings
Shares Held
VANGUARD INDEX FUNDS
5.210541%
23602267
Fidelity Salem Street Trust
0.839977%
3804857
TIAA-CREF Funds
0.83487%
3781724
Fidelity Concord Street Trust
0.752308%
3407742
NORTHERN LIGHTS FUND TRUST II
0.745579%
3377261

Global Institutional Holdings in Iovance Biotherapeutics

Funds
Holdings
Vanguard
6.66%
VANGUARD INDEX FUNDS
5.21%
iShares
4.57%
SPDR
3.07%
Fidelity Salem Street Trust
0.84%

Insights on Iovance Biotherapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, IOVA has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 months, IOVA stock has moved up by 158.8%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 712.1% return, outperforming this stock by 290.8%

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.
OrganisationIovance Biotherapeutics
Headquarters825 Industrial Road, San Carlos, CA, 94070, US
IndustryBiotechnology
CEOFrederick G. Vogt
E-voting on sharesClick here to vote

Key Management of Iovance Biotherapeutics

Name

Title

Ms. Corleen M. Roche

Chief Financial Officer

Dr. Raj K. Puri M.D., Ph.D.

Chief Regulatory Officer

Ms. Sara Pellegrino

Senior Vice President of Investor Relations & Corporate Communications

Ms. Tracy Winton

Executive Vice President of Human Resources

Mr. Kevin Smyth

Executive Vice President of Quality

Dr. Brian Gastman M.D.

Executive Vice President of Translational Medicine & Research

Dr. Frederick G. Vogt Esq., J.D., Ph.D.

Interim CEO, President, General Counsel, Corporate Secretary & Director

Dr. Igor P. Bilinsky Ph.D.

Chief Operating Officer

Mr. Daniel G. Kirby

Chief Commercial Officer

Mr. Howard B. Johnson M.B.A.

Chief Business Officer

FAQs

What is Iovance Biotherapeutics share price today?

Iovance Biotherapeutics share price today is $11.00 as on at the close of the market. Iovance Biotherapeutics share today touched a day high of $11.13 and a low of $10.69.

What is the 52 week high and 52 week low for Iovance Biotherapeutics share?

Iovance Biotherapeutics share touched a 52 week high of $11.13 on and a 52 week low of $1.76 on . Iovance Biotherapeutics stock price today i.e. is closed at $11.00,which is 1.17% down from its 52 week high and 525.00% up from its 52 week low.

What is Iovance Biotherapeutics's market capitalisation today?

Iovance Biotherapeutics market capitalisation is $0.00T as on .

How to invest in Iovance Biotherapeutics Stock (IOVA) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Iovance Biotherapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Iovance Biotherapeutics Shares that will get you 0.1364 shares as per Iovance Biotherapeutics share price of $11.00 per share as on September 26, 2026 at 8:46 am IST.

What is the minimum amount required to buy Iovance Biotherapeutics Stock (IOVA) from India?

Indian investors can start investing in Iovance Biotherapeutics (IOVA) shares with as little as ₹95.819999694824 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹958.20 in Iovance Biotherapeutics stock (as per the Rupee-Dollar exchange rate as on ). Based on Iovance Biotherapeutics share’s latest price of $11.00 as on September 26, 2026 at 8:46 am IST, you will get 0.9091 shares of Iovance Biotherapeutics. Learn more about fractional shares .

What are the returns that Iovance Biotherapeutics has given to Indian investors in the last 5 years?

Iovance Biotherapeutics stock has given -55.93% share price returns and 29.98% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?